Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma

Introduction Cellular senescence (CS) plays a critical role in cancer development, including clear cell renal carcinoma (ccRCC). Traditional RNA sequencing cannot detect precise molecular composition changes within tumors. This study aimed to analyze cellular senescence’s biochemical characteristics ccRCC using single (ScRNA-seq) and traditional (Bulk RNA-seq). Methods Researchers analyzed the of ScRNA-seq Bulk RNA-seq. They combined these approaches identify differences between malignant non-malignant phenotypes across three senescence-related pathways. Genes from pathways were used subtypes associated with senescence, new risk model was constructed. The function gene DUSP1 validated through biological experiments. Results analysis RNA-seq revealed significant identified genes constructing model. Different subgroups showed prognosis level, clinical stage grade, immune infiltration, immunotherapy, drug sensitivity. Discussion Senescence signature markers are practical biomarkers predictors typing ccRCC. Differences sensitivity different indicate that this approach could provide valuable insights into treatment options prognostic assessment for patients experiments, confirming its feasibility as novel biomarker These findings suggest targeted therapies based on mechanisms be an effective option